What are the two Chinese vaccines that would have triggered the conflict with the ambassador

Foreign Minister Felipe Solá has prematurely ordered the return of Argentina’s Ambassador to China Luis María Kreckler. Your return decree is already signed.

The decision was made while the government negotiates the purchase with China millions of doses Sinovac vaccine. And they are also discussing with the Chinese company Sinopharm, for the purchase of 11 million vaccines it would happen in March.

“We are in talks with suppliers such as Sinovac and Sinopharm in China, where tomorrow (Friday) I will have a videoconference since we have 5 months of negotiation. With Sinovac, we have a letter of intent already signed with the Butantan Institute which produces it, ”Minister of Health Ginés González García said on Thursday.

Sinopharm vaccine

The vaccine was developed by the CNBG (China National Biotech Group), affiliated with the China National Pharmaceutical Group (Sinopharm), in collaboration with the BIBP (Beijing Institute of Biological Products).

In Argentina, around 3000 volunteers between the ages of 18 and 85, who have not had the virus, are participating in a phase 3 clinical trial to assess its safety and effectiveness. Half received both doses of the vaccine and the other half received a placebo.

The study is organized by the Hospita Foundation – led by its scientific director, infectious disease specialist Pedro Cahn – with members of the Vacunar scientific committee.

Sinopharm Chairman Liu Jingzhen reported that 56 thousand people who received the coronavirus vaccine as part of the emergency use authorization application and traveled abroad from China they were not infected.

The UAE regulatory agency, where Sinopharm has been tested, said that seemed 86% effective, based on preliminary data from clinical trials.

Sinovac vaccine

The CoronaVac vaccine, manufactured by the biopharmaceutical company Sinovac, is in phase 3 clinical trials.

It can be massively applied early next year, said the president of the pharmaceutical company, Yin Weidong. It ensures that they have the capacity to manufacture nearly 300 million doses per year.

China has approved the emergency use of this vaccine candidate, as have the United Arab Emirates and Bahrain.

According to the scientific journal The Lancet, data from 144 participants in phase 1 and 600 in phase 2 clinical trials, making the vaccine ‘suitable for emergency use’.

In Brazil, clinical trials have been carried out with 13,000 volunteers. Last Friday, two million of these vaccines arrived in São Paulo, whose authorities will ask the Brazilian government for an emergency authorization to begin vaccination in January.

The State of Sao Paulo announced on Wednesday that the Sinovac vaccine has achieved the minimum efficacy and safety required for its use, although he did not specify the respective levels.

For its part, Turkey announced Thursday that it would soon receive the first units of the vaccine. The authorities claimed to have verified the effectiveness of 91.25% in the preliminary results, since phase 3 tests continue to be carried out in this country with 7,371 volunteers.

How do they work?

The two vaccines of Chinese origin – Sinovac and Sinopharm – use inactivated viruses. What they do is grow the virus in the labs. They then use dead viral particles to expose the immune system to the Covid-19 virus, without the risk of serious illness.

It is a traditional method that has been used successfully in many known vaccines, such as rabies.

China’s third vaccine

In addition, Argentina is testing another Chinese vaccine, developed by the Beijing Institute of Biotechnology, CanSino Biologics Inc.

Once again, Fundación Huiuda is leading the clinical trial, phase 3, which will be carried out in 11 health centers in the metropolitan area of ​​Buenos Aires (AMBA) and Mar del Plata. In total, in Argentina 8,000 people will be recruited.

The infectologist and scientific director of the Hospitable Foundation, Pedro Cahn, assured that the CanSino vaccine is a system similar to that of AstraZeneca, that of Gamaleya (Sputnik V) and the Janssen vaccine. They all have in common that they are mounted on an adenovirus.

One of the advantages of the CanSino Bio vaccine is that it contemplates a single dose, which it is maintained between 2 and 8 degrees, which facilitates the logistics in case of good results in the phase 3 study.

PS